3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Triple Negative Breast Neoplasms
5
Breast Neoplasms
5
Carcinoma, Non-Small-Cell Lung
4
Carcinoma, Transitional Cell
3
Neoplasm Metastasis
2
Urinary Bladder Neoplasms
1
Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma
1
Prostatic Neoplasms
1
Muscle Invasive Bladder Urothelial Carcinoma
1
Lung Neoplasms
1
Lung Diseases
1
Locally Advanced or Metastatic Unresectable Urothelial Cancer
1
Liver Failure
1
HRD Cancer
1
Extensive Stage Small Cell Lung Cancer (ES-SCLC)
1
Drug-Related Side Effects and Adverse Reactions
1
Brain Neoplasms
1
Advanced Solid Tumors
1
Interventions
Bevacizumab
21
Paclitaxel
19
Carboplatin
15
pembrolizumab
14
Specimen Handling
14
liposomal doxorubicin
12
Magnetic Resonance Spectroscopy
12
Cyclophosphamide
11
olaparib
10
Gemcitabine
10
fludarabine
9
Topotecan
8
Biopsy
8
Fulvestrant
7
niraparib
6
Nivolumab
6
palbociclib
5
Taxes
5
Immunoglobulin G
5
Doxorubicin
5
Disulfides
5
aldesleukin
4
trastuzumab deruxtecan
3
mirvetuximab soravtansine
3
binimetinib
3
Oxaliplatin
3
Cisplatin
3
AZD5305
3
1-dodecylpyridoxal
3
ulixertinib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Ovarian Neoplasms
×
sacituzumab govitecan
×
30 days
×
Clear all
No trials found.